Contingent Consideration Payable and Royalty Payments - Narrative (Details) - USD ($) $ in Thousands |
Oct. 31, 2024 |
Mar. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|---|
| Asset Acquisition [Line Items] | |||
| Contingent consideration payable | $ 6,389 | $ 7,600 | |
| ImmPACT Bio USA Inc. | |||
| Asset Acquisition [Line Items] | |||
| Asset acquisition, upfront payment | $ 30,000 | ||
| Cash acquired from acquisition | $ 11,900 | ||
| Stock issued during period, shares, acquisitions (in shares) | 37,500,000 | ||
| Asset acquisition, contingent consideration arrangements, entity shares issuable (in shares) | 12,500,000 | ||
| Asset acquisition, contingent consideration payable, shares held (in shares) | 12,500,000 |